vs
AtriCure, Inc.（ATRC）与MARCUS CORP（MCS）财务数据对比。点击上方公司名可切换其他公司
MARCUS CORP的季度营收约是AtriCure, Inc.的1.4倍（$193.5M vs $141.2M），AtriCure, Inc.同比增速更快（14.3% vs 2.8%），过去两年MARCUS CORP的营收复合增速更高（18.2% vs 10.2%）
AtriCure是一家专注于心房颤动及相关心脏病症治疗的医疗设备企业，研发并生产创新外科手术工具与疗法，主要服务北美、欧洲、亚太地区的医院、心脏外科中心及医疗机构，为微创心脏手术提供高效可靠的适配解决方案。
马库斯公司是一家美国企业，主营商业地产领域相关服务，业务覆盖美国与加拿大，提供商业地产经纪、按揭经纪、行业研究以及咨询服务，首创了由单一经纪公司独家代理房源挂牌的行业模式，目前在美加两国设有超过80家办公室，拥有员工超1800名。
ATRC vs MCS — 直观对比
营收规模更大
MCS
是对方的1.4倍
$141.2M
营收增速更快
ATRC
高出11.5%
2.8%
两年增速更快
MCS
近两年复合增速
10.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $141.2M | $193.5M |
| 净利润 | $108.0K | — |
| 毛利率 | 77.4% | — |
| 营业利润率 | 23.0% | 0.9% |
| 净利率 | 0.1% | — |
| 营收同比 | 14.3% | 2.8% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.00 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRCMCS
| Q1 26 | $141.2M | — | ||
| Q4 25 | $140.5M | $193.5M | ||
| Q3 25 | $134.3M | $210.2M | ||
| Q2 25 | $136.1M | $206.0M | ||
| Q1 25 | $123.6M | $148.8M | ||
| Q4 24 | $124.3M | $188.3M | ||
| Q3 24 | $115.9M | $232.7M | ||
| Q2 24 | $116.3M | $176.0M |
净利润ATRCMCS
| Q1 26 | $108.0K | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $-267.0K | $16.2M | ||
| Q2 25 | $-6.2M | $7.3M | ||
| Q1 25 | $-6.7M | $-16.8M | ||
| Q4 24 | — | $986.0K | ||
| Q3 24 | $-7.9M | $23.3M | ||
| Q2 24 | $-8.0M | $-20.2M |
毛利率ATRCMCS
| Q1 26 | 77.4% | — | ||
| Q4 25 | 75.0% | — | ||
| Q3 25 | 75.5% | — | ||
| Q2 25 | 74.5% | — | ||
| Q1 25 | 74.9% | — | ||
| Q4 24 | 74.5% | — | ||
| Q3 24 | 74.9% | — | ||
| Q2 24 | 74.7% | — |
营业利润率ATRCMCS
| Q1 26 | 23.0% | — | ||
| Q4 25 | 1.8% | 0.9% | ||
| Q3 25 | 0.2% | 10.8% | ||
| Q2 25 | -4.5% | 6.3% | ||
| Q1 25 | -4.8% | -13.7% | ||
| Q4 24 | -11.7% | -1.2% | ||
| Q3 24 | -6.4% | 14.1% | ||
| Q2 24 | -6.2% | 1.3% |
净利率ATRCMCS
| Q1 26 | 0.1% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | -0.2% | 7.7% | ||
| Q2 25 | -4.5% | 3.6% | ||
| Q1 25 | -5.5% | -11.3% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | -6.8% | 10.0% | ||
| Q2 24 | -6.9% | -11.5% |
每股收益（稀释后）ATRCMCS
| Q1 26 | $0.00 | — | ||
| Q4 25 | $0.04 | — | ||
| Q3 25 | $-0.01 | — | ||
| Q2 25 | $-0.13 | — | ||
| Q1 25 | $-0.14 | — | ||
| Q4 24 | $-0.33 | — | ||
| Q3 24 | $-0.17 | — | ||
| Q2 24 | $-0.17 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $146.2M | $23.4M |
| 总债务越低越好 | $61.0M | $159.0M |
| 股东权益账面价值 | $491.7M | $457.4M |
| 总资产 | $644.0M | $1.0B |
| 负债/权益比越低杠杆越低 | 0.12× | 0.35× |
8季度趋势，按日历期对齐
现金及短期投资ATRCMCS
| Q1 26 | $146.2M | — | ||
| Q4 25 | $167.4M | $23.4M | ||
| Q3 25 | $147.9M | $7.4M | ||
| Q2 25 | $117.8M | $14.9M | ||
| Q1 25 | $99.9M | $11.9M | ||
| Q4 24 | $122.7M | $40.8M | ||
| Q3 24 | $130.3M | $28.4M | ||
| Q2 24 | $114.0M | $32.8M |
总债务ATRCMCS
| Q1 26 | $61.0M | — | ||
| Q4 25 | — | $159.0M | ||
| Q3 25 | $61.9M | $162.0M | ||
| Q2 25 | $61.9M | $179.9M | ||
| Q1 25 | $61.9M | $198.9M | ||
| Q4 24 | — | $159.1M | ||
| Q3 24 | $61.9M | $173.1M | ||
| Q2 24 | $61.9M | $175.7M |
股东权益ATRCMCS
| Q1 26 | $491.7M | — | ||
| Q4 25 | $491.9M | $457.4M | ||
| Q3 25 | $476.5M | $454.3M | ||
| Q2 25 | $464.5M | $448.4M | ||
| Q1 25 | $454.6M | $441.8M | ||
| Q4 24 | $461.0M | $464.9M | ||
| Q3 24 | $465.0M | $462.3M | ||
| Q2 24 | $462.1M | $449.4M |
总资产ATRCMCS
| Q1 26 | $644.0M | — | ||
| Q4 25 | $654.2M | $1.0B | ||
| Q3 25 | $635.4M | $1.0B | ||
| Q2 25 | $608.8M | $1.0B | ||
| Q1 25 | $591.6M | $1.0B | ||
| Q4 24 | $609.3M | $1.0B | ||
| Q3 24 | $615.1M | $1.0B | ||
| Q2 24 | $597.3M | $1.1B |
负债/权益比ATRCMCS
| Q1 26 | 0.12× | — | ||
| Q4 25 | — | 0.35× | ||
| Q3 25 | 0.13× | 0.36× | ||
| Q2 25 | 0.13× | 0.40× | ||
| Q1 25 | 0.14× | 0.45× | ||
| Q4 24 | — | 0.34× | ||
| Q3 24 | 0.13× | 0.37× | ||
| Q2 24 | 0.13× | 0.39× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $48.8M |
| 自由现金流经营现金流 - 资本支出 | — | $26.4M |
| 自由现金流率自由现金流/营收 | — | 13.6% |
| 资本支出强度资本支出/营收 | — | 11.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $989.0K |
8季度趋势，按日历期对齐
经营现金流ATRCMCS
| Q1 26 | — | — | ||
| Q4 25 | $20.0M | $48.8M | ||
| Q3 25 | $26.7M | $39.1M | ||
| Q2 25 | $21.6M | $31.6M | ||
| Q1 25 | $-11.0M | $-35.3M | ||
| Q4 24 | $5.8M | $52.6M | ||
| Q3 24 | $20.0M | $30.5M | ||
| Q2 24 | $7.4M | $36.0M |
自由现金流ATRCMCS
| Q1 26 | — | — | ||
| Q4 25 | $18.4M | $26.4M | ||
| Q3 25 | $24.1M | $18.2M | ||
| Q2 25 | $19.0M | $14.7M | ||
| Q1 25 | $-13.2M | $-58.3M | ||
| Q4 24 | $3.1M | $27.1M | ||
| Q3 24 | $16.4M | $12.0M | ||
| Q2 24 | $5.0M | $16.1M |
自由现金流率ATRCMCS
| Q1 26 | — | — | ||
| Q4 25 | 13.1% | 13.6% | ||
| Q3 25 | 18.0% | 8.7% | ||
| Q2 25 | 13.9% | 7.1% | ||
| Q1 25 | -10.7% | -39.2% | ||
| Q4 24 | 2.5% | 14.4% | ||
| Q3 24 | 14.1% | 5.2% | ||
| Q2 24 | 4.3% | 9.2% |
资本支出强度ATRCMCS
| Q1 26 | — | — | ||
| Q4 25 | 1.1% | 11.6% | ||
| Q3 25 | 1.9% | 9.9% | ||
| Q2 25 | 2.0% | 8.2% | ||
| Q1 25 | 1.8% | 15.5% | ||
| Q4 24 | 2.2% | 13.5% | ||
| Q3 24 | 3.1% | 7.9% | ||
| Q2 24 | 2.1% | 11.3% |
现金转化率ATRCMCS
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 2.41× | ||
| Q2 25 | — | 4.32× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 53.31× | ||
| Q3 24 | — | 1.31× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATRC
| Appendage management | $48.4M | 34% |
| Open ablation | $39.1M | 28% |
| Other | $25.0M | 18% |
| Pain management | $22.4M | 16% |
| Minimally invasive ablation | $6.4M | 5% |
MCS
| Theatres | $123.1M | 64% |
| Concessions | $51.0M | 26% |
| Food And Beverage | $21.2M | 11% |
